Skip to main content
SpringerLink
Log in

Urinary symptoms: broadening the horizons for the copeptin assay

  • Letter
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Christ-Crain M, Fenske WK (2019) Copeptin in the differential diagnosis of hypotonic polyuria. J Endocrinol Invest. https://doi.org/10.1007/s40618-019-01087-6 [Epub ahead of print]

  2. Winzeler B, Cesana-Nigro N, Refardt J et al (2019) Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet 394(10198):587–595

    Article  CAS  Google Scholar 

  3. Cornu JN, Abrams P, Chapple CR et al (2012) A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management—a systematic review and meta-analysis. Eur Urol 62(5):877–890

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Karel Everaert, Jason M. Lazar, Joseph G. Verbalis, and Jeffrey P. Weiss for their contributions to the content and critical revisions of this correspondence.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Urology, State University of New York Downstate Health Sciences University, 450 Clarkson Avenue, Box 79, Brooklyn, NY, 11203, USA

    T. F. Monaghan

  2. Department of Neurology, Emory University School of Medicine, 12 Executive Park Drive, Room 435, Atlanta, GA, 30329, USA

    D. L. Bliwise

  3. Department of Urology, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA

    A. J. Wein

Authors
  1. T. F. Monaghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. L. Bliwise
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. J. Wein
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Monaghan, Bliwise, and Wein contributed to the content, drafting, and critical revisions of this correspondence.

Corresponding author

Correspondence to T. F. Monaghan.

Ethics declarations

Conflicts of interest

Thomas Monaghan has nothing to disclose. Dr. Bliwise has served as a consultant for Merck, Jazz, Ferring, Eisai, and Respicardia and speaker for Merck within the last three years, outside the submitted work. Dr. Wein has served as an advisor/consultant for Avadel, GTX, Acquinox, Urovant, Medtronic, and Serenity within the last three years, outside the submitted work.

Ethical approval

This correspondence was written in accordance with the Ethical Standards outlined by the Journal of Endocrinological Investigation.

Informed consent

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Monaghan, T.F., Bliwise, D.L. & Wein, A.J. Urinary symptoms: broadening the horizons for the copeptin assay. J Endocrinol Invest 43, 119–120 (2020). https://doi.org/10.1007/s40618-019-01142-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-019-01142-2

Search

Navigation